UID:
almahu_9948026016702882
Format:
1 online resource (478 pages)
ISBN:
1-281-05682-0
,
9786611056827
,
0-08-053775-8
Content:
This book offers pertinent basic science information on strategies used for the rational design and discovery of novel anticancer agents, and, in addition, translational studies involving clinical trial design and execution with these novel, mostly cytostatic agents. This book covers basic science strategies that are being used in drug discovery and preclinical evaluation focused on novel molecular targets, as well as clinical trial methodology including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the new, relatively non-cytotoxic anticancer agents.
Note:
Front Cover; Novel Anticancer Agents: Strategies for Discovery and Clinical Testing; Copyright Page; Contents; Contributors; Preface; Part I: Strategies for Drug Discovery; Chapter 1. A Survey of Novel Molecular Targets for Anticancer Drug Discovery; I. Introduction; II. Overview of Growth Factor Induced Mitogenic Signaling; III. Protein Kinases and Phosphatases; IV. Adapter Proteins; V. GTP-Binding Proteins; VI. Oncogenic Transcription Factors; VII. Apoptosis, Cell Survival, and Life Span Targets; VIII. Angiogenesis and Metastasis Molecular Factors
,
IX. Protein Degradation and Chaperoning Targets; X. Chromatin Remodeling Factors; XI. Conclusion; References; Chapter 2. Microarrays: Small Spots Produce Major Advances in Pharmacogenomics; I. Introduction to Microarrays; II. Advantages of DNA Microarrays; III. Major DNA Array Formats: Something for Everyone; IV. What is the Best Way to Interface with Microarrays?; V. Microarrays and Pharmacogenomics: Revolutionizing Discovery of New Drugs and Gene Function; VI. What Can Go Wrong in cDNA Microarray Experimentation?; VII. Array-Based Proteomics: How to Investigate Protein Complexity
,
VIII. Emerging Microarray Technologies for High-Throughput Proteome Investigation: A Technical Overview; IX. Current and Future Applications of Protein Arrays in Drug Discovery; X. How to Deal with all that Data; XI. The Future is Only Going to Get Better; References; Chapter 3. Strategies to Target Chemotherapeutics to Tumors; I. Background and Rationale; II. Antibody-Directed Enzyme Prodrug Technique; III. Passive Tumor Targeting; IV. Targeting by Binding to Tumor Cell Surface Molecules; V. Enzyme-Activated Targeting; VI. Summary and Future Directions; References
,
Chapter 4. QSAR and Pharmacophore Mapping Strategies in Novel Anticancer Drug Discovery; I. Introduction; II. Pharmacophore Definition; III. Pharmacophore Validation; IV. Conclusions; References; Chapter 5. Applications of Nuclear Magnetic Resonance and Mass Spectrometry to Anticancer Drug Discovery; I. Introduction; II. NMR in Anticancer Drug Discovery; III. Mass Spectrometry in Anticancer Drug Discovery; IV. MS/NMR Screening Assay; V. Conclusions; Acknowledgements; References; Chapter 6. Antisense Strategies for the Development of Novel Cancer Therapeutics; I. Introduction
,
II. Design and Evaluation of Antisence OligonucleotidesIII. Conclusion; Acknowledgements; References; Chapter 7. Antibodies and Vaccines as Novel Cancer Therapeutics; I. Introduction; II. Anti-Tumor Antibodies; III. Cancer Vaccines; IV. Conclusion; References; Chapter 8. Inhibitors of Apoptosis as Targets for Cancer Therapy; I. The Inhibitors of Apoptosis; II. Concluding Remarks; References; Chapter 9. Preclinical Testing and Validation of Novel Anticancer Agents; I. Introduction; II. Target Validation; III. A Generic Cascade for Anticancer Drug Discovery; IV. High-Throughput Cell-Free Screens for Activity Against the Target
,
English
Additional Edition:
ISBN 0-12-088561-1
Language:
English
